Still the Great Debate - "Fair Balance"� in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"

Brent L. Rollins

Still the Great Debate - "Fair Balance"� in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"

Research output: Contribution to journal › Article › peer-review

Abstract

The above titled paper examined the Food and Drug Administration's (FDA's) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?

Original language	American English
Journal	International Journal of Health Policy and Management
Volume	5
State	Published - Jan 1 2016

Keywords

(NOV)
Direct-to-Consumer Advertising (DTCA)
Fair Balance
Food and Drug Administration (FDA)
Notice of Violations
Office of Prescription Drug Promotion (OPDP)

Disciplines

Pharmacy and Pharmaceutical Sciences

Cite this

Still the Great Debate - "Fair Balance"� in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters". / Rollins, Brent L.
In: International Journal of Health Policy and Management, Vol. 5, 01.01.2016.

Research output: Contribution to journal › Article › peer-review

@article{2eb299fb2f954f82a8297c48bc6108fd,

title = "Still the Great Debate - {"}Fair Balance{"}� in Direct-to-Consumer Prescription Drug Advertising; Comment on {"}Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters{"}",

abstract = " The above titled paper examined the Food and Drug Administration's (FDA's) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?",

keywords = "(NOV), Direct-to-Consumer Advertising (DTCA), Fair Balance, Food and Drug Administration (FDA), Notice of Violations, Office of Prescription Drug Promotion (OPDP)",

author = "Rollins, {Brent L.}",

year = "2016",

month = jan,

day = "1",

language = "American English",

volume = "5",

journal = "International Journal of Health Policy and Management",

}

TY - JOUR

T1 - Still the Great Debate - "Fair Balance"� in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"

AU - Rollins, Brent L.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The above titled paper examined the Food and Drug Administration's (FDA's) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?

AB - The above titled paper examined the Food and Drug Administration's (FDA's) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?

KW - (NOV)

KW - Direct-to-Consumer Advertising (DTCA)

KW - Fair Balance

KW - Food and Drug Administration (FDA)

KW - Notice of Violations

KW - Office of Prescription Drug Promotion (OPDP)

UR - https://digitalcommons.pcom.edu/scholarly_papers/1689

M3 - Article

VL - 5

JO - International Journal of Health Policy and Management

JF - International Journal of Health Policy and Management

ER -

Still the Great Debate - "Fair Balance"� in Direct-to-Consumer Prescription Drug Advertising; Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters"

Abstract

Keywords

Disciplines

Other files and links

Cite this